|
| Agent | Targets | Phase | Intervention | Stage of the disease | Trial number |
|
| Sunitinib | VEGFRPDGFRc-kitRETCSF-1Rflt-3 | II | Sunitinib monotherapy | Platinum-resistant recurrent | AGO-OVAR 2.11 |
| NCT00543049 |
| (Germany) |
| II | Sunitinib monotherapy | Recurrent or refractory | DF08-056 |
| NCT00768144 |
| (United States) |
| II | Sunitinib monotherapy | Advanced and/or metastatic | CAN-NCIC-IND185 |
| NCT00388037 |
| (Canada) |
|
| Sorafenib | Raf-1VEGFRPDGFRBflt-3c-kit | II | Sorafenib maintenance versus placebo | CR after standard platinum therapy | NCT00791778 |
| II | Paclitaxel and carboplatin sorafenib | 1st line | SCRI GYN 19NCT00390611 |
| II | Paclitaxel and carboplatin sorafenib | Platinum-sensitive recurrent | CASE-CWRU-2804NCT00096200 |
| II | Topotecan sorafenib | Platinum-resistant recurrent | GYN06-111NCT00526799 |
|
| Pazopanib | VEGFRPDGFRc-kit | III | Pazopanib maintenance versus placebo | After 1st line chemo | AGO-OVAR16NCT00866697 |
| II | Pazopanib monotherapy | Recurrent | VEG104450NCT00281632 |
| I | Metronomic topotecan + pazopanib | Persistent or recurrent | NCT00800345 |
|
| XL999 | VEGFRPDGFRFGFRflt-3Src | II | XL999 monotherapy | Recurrent | NCT00277290 |
|
| Motesanib | VEGFRPDGFRc-kit | II | Motesanib monotherapy | Persistent or recurrent | NCT00574951 |
|
| Vandetanib | VEGFREGFR | II | Docetaxel vandetanib | Persistent or recurrent | SWOG-S0904NCT00872989 |
| I/II | Pegliposomal doxorubicin vandetanib | Platinum-refractory recurrent | NCT00862836 |
|